129012-04-0

Basic information

• Product Name: 6-BROMOPYRIDINE-2,3-DIAMINE
• Synonyms: 6-BROMOPYRIDINE-2,3-DIAMINE;6-Bromo-2,3-diaminopyridine;6-Bromo-2,3-pyridinediamine;6-broMopyridin-2,3-diaMine;2,3-DiaMino-6-broMopyridine
• CAS NO: 129012-04-0
• Molecular Formula: C₅H₆BrN₃
• Molecular Weight: 188.03
• EINECS: -0
• Product Categories: Building Blocks;Pyridine
• Mol File: 129012-04-0.mol

Chemical Properties

• Boiling Point: 345.208°C at 760 mmHg
• Flash Point: 162.576°C
• Appearance: /
• Density: 1.818
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.712
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 2.65±0.50(Predicted)
• CAS DataBase Reference: 6-BROMOPYRIDINE-2,3-DIAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 6-BROMOPYRIDINE-2,3-DIAMINE(129012-04-0)
• EPA Substance Registry System: 6-BROMOPYRIDINE-2,3-DIAMINE(129012-04-0)

Safety Data

• Hazardous Substances Data: 129012-04-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
6-BROMOPYRIDINE-2,3-DIAMINE is used as a key intermediate in the synthesis of new drugs, contributing to the development of innovative pharmaceuticals for various therapeutic applications.
Used in Dye Industry:
6-BROMOPYRIDINE-2,3-DIAMINE is used as a building block in the production of colorants, enabling the creation of a wide range of dyes with diverse properties and applications.
Used in Specialty Chemicals:
6-BROMOPYRIDINE-2,3-DIAMINE is used as a precursor in the synthesis of various specialty chemicals, enhancing the performance and functionality of these compounds in different industries.
Used in Material Science:
6-BROMOPYRIDINE-2,3-DIAMINE is used in the development of novel polymeric materials and coatings, improving their properties and expanding their applications in various fields.
Used in Chemical Research:
6-BROMOPYRIDINE-2,3-DIAMINE is used as a subject of study for its potential biological and environmental effects, as well as its role in various chemical reactions and processes, contributing to the advancement of scientific knowledge in these areas.

InChI:InChI=1/C5H6BrN3/c6-4-2-1-3(7)5(8)9-4/h1-2H,7H2,(H2,8,9)

Upstream product

• 84487-04-7 6-bromo-3-nitro-pyridin-2-ylamine 
• 7439-89-6 iron 
• 1254171-35-1 6-bromo-N-(4-methoxybenzyl)pyridine-2,3-diamine 
• 55304-80-8 2,6-dibromo-3-nitropyridine 
• 27048-04-0 2-amino-6-chloro-3-nitropyridine 
• 1211333-10-6 6-bromo-2-nitropyridin-3-amine 
• 13269-19-7 3-amino-2-nitropyridine 

Downstream Products

• 129012-00-6 4-(5-Bromo-1H-imidazo[4,5-b]pyridin-2-yl)-phenol 
• 219762-28-4 5-bromo-2-methyl-1H-imidazo[4,5-b]pyridine 
• 28279-52-9 5-bromo-1H-imidazo[4,5-b]pyridine 
• 1254171-37-3 N-(2-amino-6-bromopyridin-3-yl)-2-(2-chloro-6-fluorophenyl)-1H-imidazole-4-carboxamide 
• 70395-67-4 6-bromo-2,3-diphenyl-pyrido[2,3-b]pyrazine 
• 219764-81-5 3-(2-chloro-4-((cyclohexylmethyl)oxy)benzyl)-2-methyl-3H-imidazo[4,5-b]pyridine-5-carboxylic acid 
• 219762-31-9 3-(2,4-dichlorobenzyl)-2-methyl-3H-imidazo[4,5-b]pyridine-5-carbonitrile 
• 219762-32-0 1-(2,4-dichlorobenzyl)-2-methyl-1H-imidazo[4,5-b]pyridine-5-carbonitrile 

Relevant articles and documents

Synthesis, biological properties and structural study of new halogenated azolo[4,5-b]pyridines as inhibitors of CK2 kinase

The new halogenated 1H-triazolo[4,5-b]pyridines and 1H-imidazo[4,5-b]pyridines were synthesised as analogues of known CK2 inhibitors: 4,5,6,7-tetrabromo-1H-benzotriazole (TBBt) and 4,5,6,7-tetrabromo-1H-benzimidazole (TBBi). Their influence on the activity of recombinant human CK2α, CK2α’ and PIM1 kinases was determined. The most active inhibitors were di- and trihalogenated 1H-triazolo[4,5-b]pyridines (4a, 5a and 10a) with IC50 values 2.56, 3.82 and 3.26 μM respectively for CK2α. Furthermore, effect on viability of cancer cell lines MCF-7 (human breast adenocarcinoma) and CCRF-CEM (T lymphoblast leukemia) of all final compounds was evaluated. Finally, three crystal structures of complexes of CK2α1-335 with inhibitors 4a, 5a and 10a were obtained. In addition, new protocol was used to obtain high-resolution crystal structures of CK2α’Cys336Ser in complex with four inhibitors (4a, 5a, 5b, 10a).

HETEROCYCLIC COMPOUNDS AND USE THEREOF AS MODULATORS OF TYPE III RECEPTOR TYROSINE KINASES

Provided herein are heterocyclic compounds for treatment of CSF1R, FLT3, KIT, and/or PDGFRβ kinase mediated diseases. Also provided are pharmaceutical compositions comprising the compounds and methods of using the compounds and compositions.

NOVEL HETEROCYCLIC DERIVATIVES AND THEIR USES

The present invention relates to novel heterocyclic compounds useful in preparing drugs for treatment of diseases associated with various functions of the histamine 4 receptor. Especially, the said drugs are useful for treatment of inflammatory diseases, allergy, pain, nasal polyps, rhinitis, chronic sinusitis, nasal congestion, nasal itch, asthma, chronic obstructive pulmonary disease, rheumatoid arthritis, atopic dermatitis, psoriasis, eczema, pruritus, itchy skin, urticaria, idiopathic chronic urticaria, scleroderma, conjunctivitis, keratoconjunctivitis, ocular inflammation, dry eye, cardiac dysfunction, arrhythmia, atherosclerosis, multiple sclerosis, inflammatory bowel disease (including colitis, Crohn's disease, ulcerative colitis), inflammatory pain, neuropathic pain, osteoarthritic pain, autoimmune thyroid disease, immune-mediated (also known as type I) diabetes, lupus, post-operative adhesions, vestibular disorders and cancer.

NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS

This invention relates to novel compounds which are antagonists or inverse agonists at one or more of the opioid receptors, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy.

COMPOUNDS AND COMPOSITIONS AS MICROSOMAL PROSTAGLANDIN E SYNTHASE-1 INHIBITORS

Provided herein are compounds, and pharmaceutical compositions comprising such compounds, wherein the compounds are inhibitors of mPGES-1 activity. Also provided herein are methods of using such compounds and composition to treat or prevent diseases or di

Sulfonamide compounds and uses thereof as medicines

The present invention relates to a sulfonamide compound of the formula (I): wherein each symbol is as defined in the specification, a salt thereof, and a pharmaceutical composition containing same. This compound can be an effective agent for the prophylaxis and treatment of the diseases curable based on a hypoglycemic action, and the diseases curable based on a cGMP-PDE inhibitory action, a smooth muscle relaxing action, a bronchodilating action, a vasodilating action, a smooth muscle cell inhibitory action and an allergy suppressing action.

Sulfonamide compounds and medicinal use thereof

A sulfonamide compound of the formula (I):R 1 --SO 2 NHCO--A--R 2 (I)wherein R 1 is alkyl, alkenyl, alkynyl and the like; A is an optionally substituted heteropolycyclic group except benzimidazolyl, indolyl, 4,7-dihydrobenzimidazolyl and 2,3-dihydrobenzoxazinyl; X is alkylene, oxa, oxa(lower)alkylene and the like; and R 2 is optionally substituted aryl, substituted biphenylyl and the like, a salt thereof and a pharmaceutical composition comprising the same. The sulfonamide compound is effective for the diseases treatable based on their blood sugar level-depressing activity, cGMP-PDE (especially PDE-V)-inhibiting activity, smooth muscle relaxing activity, bronchodilating activity, vasodilating activity, smooth muscle cell suppressing activity, and antiallergic activity.